Navigation Links
Raptor Pharmaceuticals Closes $10 Million Private Placement
Date:6/30/2008

NOVATO, Calif., June 30 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that it raised U.S.$10 million through a private placement of 20 million units constituting an aggregate of 20 million shares of the Company's common stock and two-year warrants to purchase 10 million shares of common stock. After deducting placement agent fees, the Company raised $9.3 million in net proceeds from the private placement. The Company intends to use the net proceeds to fund programs for its drug product candidates and execute its corporate strategy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO)

Each unit was priced at $0.50 and consisted of one share of the Company's common stock and one warrant to purchase one-half share of common stock. Warrants are exercisable for two years from the date of issuance at $0.75 per share during the first year and $0.90 per share during the second year. The units have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.

Zurich-based Limetree Capital acted as the lead placement agent for the transaction.

Christopher M. Starr, Ph.D., Raptor's co-founder, director and Chief Executive Officer, stated, "We are pleased to have closed this private placement, especially given the challenging financing environment for development-stage biotech companies. We are excited about using the proceeds from this transaction for the advancement of our clinical programs, which we acquired within the past ten months and our internally developed preclinical programs. In the next six to nine months, we expect to have three clinical trials in progress including two trials add
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
4. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
5. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... to Focus on Specialty ... and Biotechnology, STAMFORD, Conn., April 21 Thomas, ... that invests in life science and,medical technology companies, today ... Entrepreneur-in-Residence in the firm,s Connecticut,office. Most recently, Dr. Tierney ...
... AB,(publ) has decided on, and successfully executed, a direct placement ... placed with a limited,group of professional investors at a price ... total for the Company before issue costs. For each,issued and ... which,gives the right to subscribe for a series B share ...
... and WINNERSH, England, April 21 Paul Capital,Healthcare ... they have,signed a financing agreement relating to frovatriptan, ... agreement, Vernalis will receive,approximately euro 18.4 million in ... Capital Healthcare will receive approximately 90 per cent,of ...
Cached Biology Technology:David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence 2Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement 2Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 2Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 3
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... A team of Columbia University Medical Center (CUMC) ... found the first direct evidence of a link between ... hallmark of asthma. The study, conducted in mice, shows ... lung is forming can cause profound changes in the ...
... the subject of a symposium on Saturday, February 15, at the ... Science in Chicago. The session, which features two members of ... will take place 10:00-11:30 a.m. CST in Grand Ballroom B of ... 2014 winner of the Golden Goose Award will be ...
... Calif.) The rapid conversion of natural lands to cement-dominated ... to a new study involving 147 cities worldwide, surprisingly high ... in urban environments to the tune of hundreds of ... city. Contrary to conventional wisdom that cities are a ...
Cached Biology News:Prenatal vitamin A deficiency tied to postnatal asthma 2Prenatal vitamin A deficiency tied to postnatal asthma 3Cities support more native biodiversity than previously thought 2Cities support more native biodiversity than previously thought 3
... P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) mediate ... lumenal surface of endothelial cells at sites ... role of PSGL-1 in mediating the interaction ... documented.MAB4092 completely blocks recognition of PSGL-1 by ...
Request Info...
... of Printing Surface (3 glass slides coated with 100 ... silicon wafer coated with 1000 Angstroms of Gold over ... PDMS Stamps (3 PDMS micropatterned stamps with series of ... 10 mm or 200 um x 10 mm lines, ...
LTBP-1 (E-20)...
Biology Products: